Placental protein 5 (PP5) in pregnancy and malignant disease: the influence of heparin binding.
The molecular mass of immunoreactive placental protein 5 (PP5) in late pregnancy blood was studied by gel filtration. The predominant form of PP5 in serum was of molecular mass 37000, whereas in heparinised plasma the molecular mass ranged upwards from 50000, with the majority of material in high molecular mass forms, thought to arise by binding of PP5 to heparin. The effect of heparin on PP5 measurements appeared to be enhanced by a serum component related to pregnancy, since addition of heparin decreased the measured level of PP5 to a greater extent in pregnancy serum than in male serum to which purified PP5 had been added. The radioimmunoassay dose-response curve was shallower for PP5 in heparinised plasma than for purified PP5 and PP5 in serum, and this may explain previous low measurements and high recoveries after chromatography. PP5 produced by a hydatidiform mole behaved in a similar manner to the placental form; PP5 form a malignant breast tumour cytosol preparation did not.
D002850:Chromatography, Gel; D004305:Dose-Response Relationship, Drug; D005260:Female; D006023:Glycoproteins; D006493:Heparin / Q000378:metabolism*; D006801:Humans; D006828:Hydatidiform Mole / Q000097:blood*; D008970:Molecular Weight; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000097:blood*; D011263:Pregnancy Trimester, Third; D011863:Radioimmunoassay / Q000379:methods
D006023:Glycoproteins; D011257:Pregnancy Proteins; C021240:tissue-factor-pathway inhibitor 2; D006493:Heparin